Ametropia
Conditions
Brief summary
LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an innovative eye drops stimulating corneal innervation. To date no study has quantified the improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.
Interventions
OTHERDescribe the evolution of dry eye between 1 month and 3 months post-LASIK
Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Age over 18 * Planned bilateral LASIK surgery * Use of Repadrop as postoperative eye drops * Patient agreement to participate
Exclusion criteria
* History of corneal pathology * Diabetes * History of treatment with REPADROP® or CACICOL® or NGF® (other eye drops which are no longer available on the market to date but which would also improve corneal healing) * Ongoing treatment with topical cyclosporine * Presence of punctal plugs * Adults who are the subject of a legal protection measure (guardianship, curators) * Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation in OSDI (Ocular Surface Disease Index) score | 3 Months | Variation in OSDI (Ocular Surface Disease Index) score between 1 month and 3 months post-LASIK. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability. |
Countries
France
Outcome results
None listed